Physician profile
Sameeksha Bhama
NPI 1699018234
$6,428.09
in general payments reported to CMS, 2019-2025
57 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $338 · 2021: $54.11 · 2022: $168 · 2023: $95.72 · 2024: $2,215 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Long Term Medical Supply Or Device Loan: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.78 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,630.41 | 2019-2025 | |
| Janssen Biotech, INC. | $565.15 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Genentech USA, INC. | $388.04 | 2019 | |
| Lilly USA, LLC | $339.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $280.14 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $246.65 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $218.88 | 2019-2025 | Keytruda, Welireg |
| Pfizer INC. | $202.62 | 2020-2025 | |
| Amgen INC. | $162.30 | 2019-2022 | |
| Genzyme Corporation | $131.70 | 2024-2025 | |
| Celgene Corporation | $129.99 | 2019-2024 | Reblozyl |
| Tempus Ai, INC | $129.55 | 2024 | |
| Incyte Corporation | $108.07 | 2019-2025 | Monjuvi, Jakafi |
| Abbvie INC. | $107.48 | 2021-2025 | |
| Gilead Sciences, INC. | $103.10 | 2024-2025 | Trodelvy |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameeksha Bhama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.